FDA Grants Fast Track Designation for Trethera's TRE-515
The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Trethera Corporation's TRE-515, a KRAS G12C inhibitor, for the treatment of non-small cell lung cancer.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.